



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2024





© 2025 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions




HIV/AIDS Drug Treatment Program
Monthly Report

1.1 Distribution of males and females on antiretroviral therapy
in British Columbia by Health Authority

December 2024

N = 7723




Health Authority	Male	Female	All
FRASER	1619	503	2122
INTERIOR	498	118	616
NORTHERN	180	81	261
VANCOUVER COASTAL	3213	446	3659
VANCOUVER ISLAND	883	170	1053
	6393	1318	7711
	Unknown/not stated:		12
	Total:		7723

Definitions:
On antiretroviral therapy defined as being on treatment in the current month
Unknown/not stated defined as being on treatment in the current month, and city of residence unknown
Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2019 - December 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (December 2019 - December 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (December 2019 - December 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (December 2019 - December 2024)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2019 - December 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2019 - December 2024)






1.8 Active and Inactive Participants (December 2019 - December 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2019 - December 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2019 - December 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2019 - December 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2019 - December 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2019 - December 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2019 - December 2024)






**1.15 Distribution of Participants on Non-Nucleosides
at the time of first start of ARV Therapy by INGREDIENT**

(December 2019 - December 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2019 - December 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(December 2019 - December 2024)






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2019 - December 2024)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2019 - December 2024)**






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2019 - December 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2019 - December 2024)





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	2	0	2	0		2	<40	3
1988	34	3	0	3	1	460	3	<40	4
1989	31	45	1	46	18	490	44	<40	3
1990	30	46	1	47	19	530	40	<40	3
1991	30	33	3	36	16	585	35	<40	3
1992	30	46	4	50	19	630	42	<40	3
1993	29	108	14	122	62	600	117	<40	3
1994	28	66	9	75	32	510	65	<40	3
1995	27	112	20	132	67	550	122	<40	3
1996	26	284	45	329	162	650	309	<40	3
1997	24	252	27	279	150	615	257	<40	3
1998	23	163	35	198	111	610	175	<40	3
1999	23	136	37	173	101	570	152	<40	3
2000	23	104	25	129	69	660	116	<40	3
2001	23	101	26	127	60	620	111	<40	3
2002	22	113	20	133	70	580	116	<40	3
2003	21	126	24	150	82	610	132	<40	3
2004	20	132	35	167	96	660	149	<40	3
2005	19	162	43	205	122	635	190	<40	3
2006	18	157	39	196	112	600	171	<40	3
2007	17	216	36	252	135	680	226	<40	3
2008	16	253	55	308	188	650	276	<40	3
2009	15	280	60	340	189	660	306	<40	3
2010	14	243	62	305	186	680	274	<40	3
2011	13	294	65	359	195	690	311	<40	3
2012	12	256	63	319	161	730	282	<40	3
2013	11	235	61	296	157	700	263	<40	3
2014	10	257	39	296	152	800	253	<40	3
2015	9	238	43	281	150	720	246	<40	3
2016	8	213	46	259	132	685	220	<40	3
2017	7	192	32	224	123	690	191	<40	3
2018	6	166	42	208	114	780	184	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	5	210	37	247	153	680	221	<40	3
2020	4	160	49	209	125	760	177	<40	3
2021	3	178	32	210	122	655	190	<40	3
2022	2	232	48	280	180	690	255	<40	3
2023	2	265	65	330	212	610	301	<40	3
2024	1	300	74	374	294	570	359	<40	3
Total:		6379	1317	7696					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1215	640
APR-2023	7553	796	1761	<40	1084	630
MAY-2023	7592	786	1933	<40	1238	645
JUN-2023	7599	787	1841	<40	1098	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1041	630
SEP-2023	7609	797	1775	<40	1068	645
OCT-2023	7610	804	1887	<40	1152	620
NOV-2023	7612	797	1854	<40	1099	650
DEC-2023	7603	801	1549	<40	915	640
JAN-2024	7642	792	1973	<40	1174	650
FEB-2024	7647	781	1773	<40	1038	620
MAR-2024	7636	790	1681	<40	989	650
APR-2024	7670	786	1943	<40	1228	660
MAY-2024	7687	787	1880	<40	1078	660
JUN-2024	7687	784	1696	<40	1023	650
JUL-2024	7718	786	1809	<40	1026	610
AUG-2024	7710	782	1866	<40	1092	653
SEP-2024	7698	791	1657	<40	987	650
OCT-2024	7727	787	2012	<40	1111	650
NOV-2024	7704	793	1777	<40	1002	660
DEC-2024	7723	796	1583	<40	917	660

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	760	218	66	<40	47	560
MAY-2023	726	239	65	<40	48	430
JUN-2023	708	200	57	<40	39	460
JUL-2023	739	182	68	<40	50	565
AUG-2023	738	188	63	<40	40	595
SEP-2023	725	207	55	<40	41	540
OCT-2023	735	209	60	<40	46	625
NOV-2023	742	203	65	<40	46	515
DEC-2023	751	192	47	<40	35	473
JAN-2024	710	219	67	<40	49	520
FEB-2024	707	233	58	<40	41	560
MAR-2024	721	201	66	<40	46	565
APR-2024	704	228	67	<40	57	530
MAY-2024	703	215	57	<40	41	560
JUN-2024	718	190	59	<40	36	459
JUL-2024	707	196	53	<40	29	530
AUG-2024	721	197	71	<40	44	595
SEP-2024	727	177	55	<40	38	595
OCT-2024	720	186	59	<40	40	495
NOV-2024	757	172	62	<40	36	600
DEC-2024	751	188	60	<40	40	665

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14767
FEB-2023	7505	787	10	11	158	204	-45	14791
MAR-2023	7532	756	15	21	197	176	27	14825
APR-2023	7531	760	13	11	176	169	-1	14854
MAY-2023	7575	726	7	15	205	165	44	14898
JUN-2023	7577	708	14	17	168	165	3	14933
JUL-2023	7555	739	11	11	164	181	-22	14964
AUG-2023	7577	738	11	13	217	192	22	15009
SEP-2023	7579	725	14	5	179	163	2	15029
OCT-2023	7579	735	18	10	170	160	0	15060
NOV-2023	7578	742	18	9	182	171	-1	15096
DEC-2023	7574	751	14	13	169	169	-4	15129
JAN-2024	7613	710	16	11	204	159	39	15161
FEB-2024	7620	707	17	11	184	165	7	15193
MAR-2024	7616	721	12	13	183	185	-4	15228
APR-2024	7647	704	17	20	197	168	31	15274
MAY-2024	7666	703	12	16	191	173	19	15311
JUN-2024	7678	718	5	23	173	177	12	15354
JUL-2024	7697	707	15	10	185	159	19	15387
AUG-2024	7687	721	13	15	164	167	-10	15420
SEP-2024	7675	727	9	7	182	186	-12	15449
OCT-2024	7704	720	8	15	201	172	29	15491
NOV-2024	7675	757	14	9	180	199	-29	15519
DEC-2024	7696	751	15	10	195	169	21	15551

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	899	6237	433	41	7610	11.81%	81.96%	5.69%	0.54%	100.00%
NOV-2023	920	6210	441	41	7612	12.09%	81.58%	5.79%	0.54%	100.00%
DEC-2023	938	6191	434	40	7603	12.34%	81.43%	5.71%	0.53%	100.00%
JAN-2024	954	6214	432	42	7642	12.48%	81.31%	5.65%	0.55%	100.00%
FEB-2024	974	6198	436	39	7647	12.74%	81.05%	5.70%	0.51%	100.00%
MAR-2024	993	6159	440	44	7636	13.00%	80.66%	5.76%	0.58%	100.00%
APR-2024	1003	6184	437	46	7670	13.08%	80.63%	5.70%	0.60%	100.00%
MAY-2024	1026	6188	434	39	7687	13.35%	80.50%	5.65%	0.51%	100.00%
JUN-2024	1035	6181	429	42	7687	13.46%	80.41%	5.58%	0.55%	100.00%
JUL-2024	1063	6184	434	37	7718	13.77%	80.12%	5.62%	0.48%	100.00%
AUG-2024	1084	6156	431	39	7710	14.06%	79.84%	5.59%	0.51%	100.00%
SEP-2024	1127	6102	426	43	7698	14.64%	79.27%	5.53%	0.56%	100.00%
OCT-2024	1171	6087	428	41	7727	15.15%	78.78%	5.54%	0.53%	100.00%
NOV-2024	1178	6070	417	39	7704	15.29%	78.79%	5.41%	0.51%	100.00%
DEC-2024	1202	6057	424	40	7723	15.56%	78.43%	5.49%	0.52%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2904 39%	1 3%	1895 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	935 13%	29 94%	4573 61%
NOV-2023	1 3%	2891 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3783 51%	7 20%	918 12%	34 97%	4585 61%
DEC-2023	6 18%	2874 39%	4 12%	1831 25%	0 0%	13 0%	25 76%	3820 51%	3 9%	895 12%	27 82%	4595 62%
JAN-2024	9 29%	2881 38%	8 26%	1831 24%	0 0%	13 0%	21 68%	3866 52%	2 6%	890 12%	22 71%	4633 62%
FEB-2024	7 22%	2868 38%	4 13%	1795 24%	0 0%	13 0%	22 69%	3896 52%	3 9%	864 12%	25 78%	4641 62%
MAR-2024	2 6%	2845 38%	0 0%	1759 23%	0 0%	13 0%	30 86%	3927 52%	3 9%	844 11%	33 94%	4656 62%
APR-2024	10 22%	2844 38%	5 11%	1742 23%	0 0%	13 0%	34 74%	3968 53%	3 7%	843 11%	36 78%	4690 62%
MAY-2024	4 11%	2822 37%	1 3%	1706 23%	0 0%	12 0%	31 84%	4018 53%	2 5%	832 11%	33 89%	4734 63%
JUN-2024	2 5%	2817 37%	2 5%	1691 22%	0 0%	13 0%	37 86%	4047 54%	4 9%	801 11%	41 95%	4738 63%
JUL-2024	4 13%	2812 37%	1 3%	1667 22%	0 0%	13 0%	24 75%	4077 54%	4 13%	800 11%	28 88%	4763 63%
AUG-2024	2 6%	2796 37%	0 0%	1633 22%	0 0%	13 0%	29 88%	4097 54%	3 9%	783 10%	31 94%	4772 63%
SEP-2024	4 14%	2797 37%	0 0%	1600 21%	0 0%	13 0%	22 76%	4113 54%	4 14%	769 10%	25 86%	4770 63%
OCT-2024	2 5%	2789 37%	1 2%	1555 21%	0 0%	13 0%	39 93%	4171 55%	2 5%	755 10%	40 95%	4812 63%
NOV-2024	7 26%	2744 36%	5 19%	1499 20%	0 0%	11 0%	19 70%	4193 55%	3 11%	740 10%	20 74%	4822 64%
DEC-2024	6 19%	2757 36%	4 13%	1481 20%	0 0%	11 0%	24 75%	4223 56%	3 9%	736 10%	26 81%	4837 64%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	876 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	866 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	229 21%	0 0%	852 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAR-2024	0 0%	225 21%	1 100%	840 77%	0 0%	30 3%	0 0%	0 0%	0 0%	0 0%
APR-2024	0 0%	224 21%	3 100%	835 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAY-2024	0 0%	221 20%	1 100%	828 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUN-2024	1 50%	214 20%	1 50%	813 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JUL-2024	0 0%	216 21%	0 0%	805 77%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
AUG-2024	0 0%	208 20%	0 0%	785 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
SEP-2024	0 0%	203 20%	1 100%	773 77%	0 0%	27 3%	0 0%	0 0%	0 0%	0 0%
OCT-2024	0 0%	197 20%	2 100%	756 77%	0 0%	27 3%	0 0%	0 0%	0 0%	0 0%
NOV-2024	0 0%	190 20%	1 100%	743 78%	0 0%	28 3%	0 0%	0 0%	0 0%	0 0%
DEC-2024	0 0%	184 19%	0 0%	739 78%	0 0%	26 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	238 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	242 26%	0 0%	209 23%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	250 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	257 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%
MAR-2024	0 0%	260 28%	1 100%	190 21%	0 0%	80 9%	0 0%	205 22%	0 0%	181 20%
APR-2024	0 0%	261 29%	0 0%	190 21%	0 0%	82 9%	0 0%	203 22%	0 0%	180 20%
MAY-2024	0 0%	262 29%	0 0%	186 21%	0 0%	80 9%	0 0%	205 23%	0 0%	175 19%
JUN-2024	0 0%	262 29%	0 0%	182 20%	0 0%	79 9%	0 0%	198 22%	0 0%	172 19%
JUL-2024	0 0%	270 30%	0 0%	176 20%	0 0%	78 9%	0 0%	194 22%	1 100%	172 19%
AUG-2024	0 0%	272 31%	0 0%	174 20%	0 0%	78 9%	0 0%	187 21%	0 0%	171 19%
SEP-2024	0 0%	275 31%	2 100%	172 19%	0 0%	76 9%	0 0%	185 21%	0 0%	179 20%
OCT-2024	0 0%	283 32%	0 0%	168 19%	0 0%	72 8%	0 0%	177 20%	0 0%	175 20%
NOV-2024	1 50%	287 34%	0 0%	162 19%	0 0%	70 8%	0 0%	159 19%	1 50%	173 20%
DEC-2024	0 0%	303 36%	0 0%	157 19%	0 0%	71 8%	0 0%	149 18%	0 0%	167 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir				cabotegravir				dolutegravir				elvitegravir				fostemsavir				maraviroc				raltegravir			
	Initial		All		Initial		All		Initial		All		Initial		All		Initial		All		Initial		All		Initial		All	
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2492	41%	0	0%	269	4%	0	0%	2	0%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2476	41%	0	0%	255	4%	0	0%	2	0%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2482	41%	2	6%	259	4%	0	0%	2	0%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3084	50%	0	0%	0	0%	4	15%	2498	41%	1	4%	258	4%	0	0%	2	0%	0	0%	18	0%	0	0%	274	4%
MAY-2023	28	67%	3138	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	2	0%	0	0%	18	0%	0	0%	278	5%
JUN-2023	26	81%	3197	51%	0	0%	5	0%	6	19%	2509	40%	0	0%	248	4%	0	0%	2	0%	0	0%	18	0%	0	0%	267	4%
JUL-2023	25	83%	3218	52%	0	0%	5	0%	5	17%	2499	40%	0	0%	247	4%	0	0%	2	0%	0	0%	18	0%	0	0%	256	4%
AUG-2023	33	79%	3258	52%	0	0%	7	0%	6	14%	2495	40%	1	2%	245	4%	0	0%	2	0%	0	0%	18	0%	2	5%	253	4%
SEP-2023	15	79%	3289	52%	0	0%	8	0%	4	21%	2500	40%	0	0%	238	4%	0	0%	2	0%	0	0%	18	0%	0	0%	249	4%
OCT-2023	22	76%	3298	52%	0	0%	7	0%	7	24%	2523	40%	0	0%	241	4%	0	0%	2	0%	0	0%	18	0%	0	0%	248	4%
NOV-2023	27	82%	3327	53%	0	0%	9	0%	6	18%	2518	40%	0	0%	233	4%	0	0%	1	0%	0	0%	17	0%	0	0%	244	4%
DEC-2023	24	77%	3365	53%	0	0%	13	0%	7	23%	2506	40%	0	0%	226	4%	0	0%	2	0%	0	0%	16	0%	0	0%	237	4%
JAN-2024	20	65%	3418	53%	1	3%	16	0%	10	32%	2520	39%	0	0%	224	4%	0	0%	2	0%	0	0%	18	0%	0	0%	234	4%
FEB-2024	21	66%	3453	54%	0	0%	15	0%	10	31%	2516	39%	0	0%	219	3%	0	0%	2	0%	0	0%	18	0%	1	3%	231	4%
MAR-2024	30	88%	3498	54%	0	0%	17	0%	4	12%	2500	39%	0	0%	220	3%	0	0%	3	0%	0	0%	17	0%	0	0%	225	3%
APR-2024	34	76%	3545	55%	0	0%	17	0%	11	24%	2497	38%	0	0%	216	3%	0	0%	2	0%	0	0%	18	0%	0	0%	225	3%
MAY-2024	29	78%	3586	55%	0	0%	19	0%	8	22%	2488	38%	0	0%	213	3%	0	0%	2	0%	0	0%	15	0%	0	0%	222	3%
JUN-2024	37	88%	3614	55%	0	0%	21	0%	5	12%	2488	38%	0	0%	207	3%	0	0%	2	0%	0	0%	17	0%	0	0%	218	3%
JUL-2024	22	67%	3650	55%	1	3%	25	0%	6	18%	2500	38%	4	12%	212	3%	0	0%	2	0%	0	0%	17	0%	0	0%	213	3%
AUG-2024	29	88%	3683	56%	0	0%	26	0%	4	12%	2487	38%	0	0%	204	3%	0	0%	2	0%	0	0%	17	0%	0	0%	207	3%
SEP-2024	21	78%	3700	56%	0	0%	32	0%	5	19%	2495	38%	1	4%	200	3%	0	0%	2	0%	0	0%	16	0%	0	0%	205	3%
OCT-2024	39	93%	3758	56%	0	0%	34	1%	3	7%	2508	38%	0	0%	198	3%	0	0%	2	0%	0	0%	15	0%	0	0%	199	3%
NOV-2024	19	70%	3791	57%	1	4%	33	0%	7	26%	2487	37%	0	0%	191	3%	0	0%	2	0%	0	0%	16	0%	0	0%	193	3%
DEC-2024	24	75%	3819	57%	0	0%	33	0%	8	25%	2522	37%	0	0%	185	3%	0	0%	2	0%	0	0%	16	0%	0	0%	187	3%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	615	8.08	611	8.03	4808	63.18	897	11.79	618	8.12	61	0.80
NOV-2023	611	8.03	599	7.87	4799	63.05	918	12.06	624	8.20	61	0.80
DEC-2023	593	7.80	596	7.84	4808	63.24	936	12.31	614	8.08	56	0.74
JAN-2024	583	7.63	585	7.66	4856	63.54	952	12.46	609	7.97	57	0.75
FEB-2024	564	7.38	586	7.66	4861	63.57	971	12.70	609	7.96	56	0.73
MAR-2024	543	7.11	580	7.60	4846	63.46	991	12.98	618	8.09	58	0.76
APR-2024	538	7.01	570	7.43	4884	63.68	1000	13.04	621	8.10	57	0.74
MAY-2024	536	6.97	566	7.36	4902	63.77	1023	13.31	607	7.90	53	0.69
JUN-2024	526	6.84	556	7.23	4910	63.87	1033	13.44	606	7.88	56	0.73
JUL-2024	520	6.74	541	7.01	4938	63.98	1060	13.73	605	7.84	54	0.70
AUG-2024	506	6.56	537	6.96	4933	63.98	1081	14.02	602	7.81	51	0.66
SEP-2024	485	6.30	530	6.88	4911	63.80	1124	14.60	595	7.73	53	0.69
OCT-2024	468	6.06	512	6.63	4937	63.89	1168	15.12	594	7.69	48	0.62
NOV-2024	465	6.04	490	6.36	4946	64.20	1176	15.26	581	7.54	46	0.60
DEC-2024	457	5.92	480	6.22	4950	64.09	1199	15.53	588	7.61	49	0.63

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	7	495
APR-2023	11	0	3	1	1	4	440
MAY-2023	15	2	1	2	5	1	367
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	2	2	255
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	13	1	0	3	0	8	592
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281
MAR-2024	13	3	2	1	1	4	250
APR-2024	20	0	4	6	1	9	364
MAY-2024	16	2	3	3	1	6	320
JUN-2024	23	1	1	10	4	7	340
JUL-2024	10	0	1	3	3	2	374
AUG-2024	15	3	2	4	3	3	322
SEP-2024	7	0	1	4	1	1	280
OCT-2024	15	6	0	3	3	3	298
NOV-2024	9	3	0	3	2	1	270
DEC-2024	10	1	3	2	2	2	270

Definitions:**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)**Baseline CD4** is defined as most recent CD4 test before ARV start



2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12447	3802
FEB-2023	12435	3787
MAR-2023	12442	3786
APR-2023	12417	3752
MAY-2023	12425	3730
JUN-2023	12398	3692
JUL-2023	12425	3715
AUG-2023	12422	3697
SEP-2023	12409	3685
OCT-2023	12393	3661
NOV-2023	12379	3648
DEC-2023	12400	3656
JAN-2024	12410	3664
FEB-2024	12423	3671
MAR-2024	12455	3686
APR-2024	12480	3691
MAY-2024	12488	3688
JUN-2024	12498	3668
JUL-2024	12495	3663
AUG-2024	12481	3643
SEP-2024	12502	3663
OCT-2024	12506	3646
NOV-2024	12501	3638
DEC-2024	12500	3636

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






HIV/AIDS Drug Treatment Program


Monthly Report

3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7723
Dec-2024

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Dec-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	6
	35-49	12	12	6
	50+	33	50	20
	Total HSDA:	51	68	32
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	74	105	55
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	478	646	359
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	19
	35-49	*	*	32
	50+	*	*	119
	Total HSDA:	235	328	170
Total HA:		838	1147	616

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	83	84	*
	35-49	202	219	*
	50+	548	839	*
Total HA:		838	1147	616

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	163	227	118
Male	675	920	498

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	616	56	670	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	28	13
	5 years or more	13	10
	<5 years	10	9
	Total HSDA:	51	32
KOOTENAY BOUNDARY	10 years or more	54	39
	5 years or more	11	8
	<5 years	9	8
	Total HSDA:	74	55
OKANAGAN	10 years or more	307	230
	5 years or more	83	59
	<5 years	88	70
	Total HSDA:	478	359
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	145	107
	5 years or more	42	25
	<5 years	48	38
	Total HSDA:	235	170
Total HA:		838	616

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	534	389
	5 years or more	149	102
	<5 years	155	125
Total HA:		838	616

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	54	102	13	30
KOOTENAY BOUNDARY	77	140	20	42
OKANAGAN	245	1105	53	331
THOMPSON/CARIBOO/SHUSWAP	152	587	31	138
Total:	528	1934	117	541

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	125

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	49	50	36
	35-49	112	116	76
	50+	279	391	211
	Total HSDA:	446	563	329
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1184	1612	890
FRASER SOUTH	0-19	7	7	6
	20-34	140	146	120
	35-49	320	347	258
	50+	659	1012	519
	Total HSDA:	1126	1512	903
Total HA:		2756	3687	2122

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	16	16	15
	20-34	324	333	262
	35-49	790	847	608
	50+	1626	2491	1237
Total HA:		2756	3687	2122

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	659	849	503
Male	2097	2838	1619

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2122	53	667	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	286	218
	5 years or more	76	43
	<5 years	84	68
	Total HSDA:	446	329
FRASER NORTH	10 years or more	755	545
	5 years or more	211	164
	<5 years	218	181
	Total HSDA:	1184	890
FRASER SOUTH	10 years or more	680	524
	5 years or more	195	152
	<5 years	251	227
	Total HSDA:	1126	903
Total HA:		2756	2122

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1721	1287
	5 years or more	482	359
	<5 years	553	476
Total HA:		2756	2122

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	155	562	33	67
FRASER NORTH	269	1664	33	242
FRASER SOUTH	235	1926	44	540
Total:	659	4152	110	849

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	217
FRASER NORTH	727
FRASER SOUTH	482
Total:	1426

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	374	553	287
RICHMOND	20-34	28	29	22
	35-49	61	62	47
	50+	127	185	103
	Total HSDA:	216	276	172
VANCOUVER	0-19	8	8	7
	20-34	385	398	284
	35-49	1208	1350	815
	50+	3007	5500	2094
	Total HSDA:	4608	7256	3200
Total HA:		5198	8085	3659

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	11
	20-34	442	456	324
	35-49	1350	1499	924
	50+	3394	6118	2400
Total HA:		5198	8085	3659

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	585	980	446
Male	4613	7105	3213

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3659	56	670	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	265	203
	5 years or more	55	44
	<5 years	54	40
	Total HSDA:	374	287
RICHMOND	10 years or more	123	97
	5 years or more	38	28
	<5 years	55	47
	Total HSDA:	216	172
VANCOUVER	10 years or more	3328	2263
	5 years or more	683	473
	<5 years	597	464
	Total HSDA:	4608	3200
Total HA:		5198	3659

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3716	2563
	5 years or more	776	545
	<5 years	706	551
Total HA:		5198	3659

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	198	579	37	58
RICHMOND	48	334	10	109
VANCOUVER	705	12131	208	5425
Total:	951	13044	255	5592

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	61

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	358	535	285
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	146	201	118
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	868	1238	650
Total HA:		1372	1974	1053

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	104	111	68
	35-49	309	345	233
	50+	953	1512	746
Total HA:		1372	1974	1053

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	225	329	170
Male	1147	1645	883

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1053	57	610	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	241	195
	5 years or more	67	46
	<5 years	50	44
	Total HSDA:	358	285
NORTH VANCOUVER ISLAND	10 years or more	106	88
	5 years or more	24	15
	<5 years	16	15
	Total HSDA:	146	118
SOUTH VANCOUVER ISLAND	10 years or more	549	399
	5 years or more	158	115
	<5 years	161	136
	Total HSDA:	868	650
Total HA:		1372	1053

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	896	682
	5 years or more	249	176
	<5 years	227	195
Total HA:		1372	1053

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.12 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	212	961	67	206
NORTH VANCOUVER ISLAND	158	367	31	65
SOUTH VANCOUVER ISLAND	236	2058	43	605
Total:	606	3386	141	876

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	83
NORTH VANCOUVER ISLAND	50
SOUTH VANCOUVER ISLAND	133
Total:	266

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	9	9	7
	35-49	20	23	14
	50+	32	42	20
	Total HSDA:	61	74	41
NORTH WEST	20-34	*	5	*
	35-49	*	35	*
	50+	*	88	*
	Total HSDA:	79	128	61
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	208	318	159
Total HA:		348	520	261

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		348	520	261

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	117	180	81
Male	231	340	180

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	261	54	590	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)



4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	33	*
	5 years or more	8	*
	<5 years	20	*
	Total HSDA:	61	41
NORTH WEST	10 years or more	55	41
	5 years or more	11	8
	<5 years	13	12
	Total HSDA:	79	61
NORTHERN INTERIOR	10 years or more	132	104
	5 years or more	46	29
	<5 years	30	26
	Total HSDA:	208	159
Total HA:		348	261

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	220	163
	5 years or more	65	41
	<5 years	63	57
Total HA:		348	261

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.15 Distribution of ARV Prescribers in BC-CfE Registries NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	38	51	2	*
NORTH WEST	90	173	15	*
NORTHERN INTERIOR	128	526	24	*
Total:	256	750	41	234

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	8
NORTH WEST	26
NORTHERN INTERIOR	20
Total:	54

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	30	51	17
	THOMPSON/CARIBOO/SHUSWAP	28	59	20
	Total HA:	70	131	47
FRASER	FRASER EAST	34	51	26
	FRASER NORTH	49	93	39
	FRASER SOUTH	79	118	57
	Total HA:	162	262	122
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	30	57	*
	RICHMOND	5	11	*
	VANCOUVER	428	920	*
	Total HA:	463	988	369
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	85	40
	NORTH VANCOUVER ISLAND	17	32	14
	SOUTH VANCOUVER ISLAND	50	100	37
	Total HA:	116	217	91
NORTHERN	NORTH EAST	14	18	12
	NORTH WEST	35	71	26
	NORTHERN INTERIOR	71	125	57
	Total HA:	120	214	95
Total:		931	1812	724

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	594	1167	459
Female	337	645	265

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	724	54	550	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose of RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

